MozCOVID SARS-CoV-2 community seroprevalence Methods (Briefly)

To date three community seroepidemiological cross-sectional studies have been conducted in the Manhiça district, with a sample size of 1201 subjects randomly selected from the Demographic Surveillance System maintained by the Manhiça Health Research Center. From each participant, blood samples were collected to investigate the presence of anti-SARS-CoV-2 antibodies. Additionally, nasopharyngeal (NP) swabs were collected from a subsample of the 1201 subjects to determine the community prevalence of infection by SARS-CoV-2.

Seroprevalence and Prevalence Overall

Table 1. Overall seroprevalence and prevalence evolution during the 3 cross-sectional studies conducted in the Manhiça district

cross period enrolled seroprevalence prevalence
Cross 1 April-June 2021 1201 27.6 4.0
Cross 2 October-November 2021 1201 63.6 0.7
Cross 3 January-February 2022 1201 91.2 10.1

Seroprevalence and prevalence between age groups in cross-sectionals

Fig 1. Seroprevalence and prevalence between age groups in cross-sectionals, Manhiça district

Evolution of Seroprevalence in Administrative Post of Manhiça District Between Cross-sectionals

The following plot presents the level of seroprevalence rate by each administrative post of the Manhiça district during each of the cross-sectional studies.

Fig 2. Evolution of Seroprevalence in Administrative Post of Manhiça District Between Cross-sectionals.

Click here to return